Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | APLNR | P35414 | 4/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.34 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172181 | 1.00 | NPY1R (0.35) | NPY1RNPY2RNPY4RF2APLNR | |
| SCHEMBL29630656 | 0.89 | DPP4 (0.35) | NPY1RNPY2RNPY4RF2C5AR1 | |
| SCHEMBL30638816 | 0.88 | MME (0.35) | F2 | |
| SCHEMBL30553466 | 0.88 | DPP7 (0.40) | NPY1RNPY2RNPY4RNOD1 | |
| SCHEMBL29871229 | 0.87 | NOD1 (0.39) | NPY1RNPY2RNPY4RNOD1 | |
| SCHEMBL29590459 | 0.87 | MME (0.38) | NPY1RNPY2RNPY4RANPEP | |
| SCHEMBL29630607 | 0.87 | MME (0.38) | NPY1RNPY2RNPY4RANPEP | |
| SCHEMBL31482979 | 0.87 | MME (0.38) | NPY1RNPY2RNPY4RANPEP | |
| SCHEMBL31279825 | 0.86 | MME (0.37) | F2GLP1RNOD1 | |
| SCHEMBL29630385 | 0.86 | BACE1 (0.39) | NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070949-A1 | POLYPEPTIDES HAVING DEAMIDASE INHIBITOR ACTIVITY | NOVOZYMES A/S (DK) | 2026-03-12 | — | — | US | disclosed |
| US-20250215412-A1 | Fusion Polypeptides with Deamidase Inhibitor and Deamidase Domains | NOVOZYMES A/S (DK) | 2025-07-03 | — | — | US | disclosed |
| EP-4242303-A1 | FUSION POLYPEPTIDES WITH DEAMIDASE INHIBITOR AND DEAMIDASE DOMAINS | Novozymes A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070949-A1 | POLYPEPTIDES HAVING DEAMIDASE INHIBITOR ACTIVITY | FBL, DPEP1, DUT | NPY1R 2492/4885NPY2R 3356/4885NPY4R 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.